Akero First To Show Benefit In Cirrhotic NASH Patients

3D illustration of many arrows symbols pointing in the same direction and one arrow going back. Concept of regression.
In a small sample, Akero's EFX showed an ability to reverse cirrhosis in NASH patients

More from Clinical Trials

More from R&D